CytoMed Therapeutics
GDTC
2 hedge funds and large institutions have $20.7K invested in CytoMed Therapeutics in 2023 Q3 according to their latest regulatory filings, with 1 funds opening new positions, 1 increasing their positions, reducing their positions, and closing their positions.
12,427% more capital invested
Capital invested by funds: $165 → $20.7K (+$20.5K)
100% more funds holding
Funds holding: 1 → 2 (+1)
0.05% more ownership
Funds ownership: 0% → 0.05% (+0.05%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SSG
Summit Securities Group
New York
|
+$20.4K |
| 2 |
UBS Group
Zurich,
Switzerland
|
+$1.6K |
Top Sellers
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
SSG
1
Summit Securities Group
New York
| $19K | +$20.4K | +5,407 | New |
|
|
2
UBS Group
Zurich,
Switzerland
| $1.67K | +$1.6K | +423 | +783% |
|
GDTC Hedge Fund Activity: Q3 2023 in Review
2 of the 6,301 institutional investors tracked by Wall St. Rank reported a position in CytoMed Therapeutics (GDTC) for Q3 2023, worth a combined $20.7K — up 12,427% from $165 a quarter earlier.
Buyers outnumbered sellers: 1 fund opened new GDTC positions and 0 closed out — a net gain of 1 holder — while 1 added to existing stakes and 0 trimmed.
The largest buyer was Summit Securities Group, opening a new position worth an estimated $20.4K.
- 2 institutional investors held CytoMed Therapeutics (GDTC) as of Q3 2023, up from 1 in Q2 2023.
- Funds reported $20.7K of CytoMed Therapeutics stock for Q3 2023, up 12,427% quarter-over-quarter.
- 1 fund opened new CytoMed Therapeutics positions in Q3 2023 and 0 closed out, a net change of +1 holder.
- The largest CytoMed Therapeutics buyer in Q3 2023 was Summit Securities Group, an estimated $20.4K added.
Based on aggregated 13F filings for Q3 2023.